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Abstract
Atopic dermatitis (AD) is a common inflammatory skin disease caused by multiple genetic and environmental factors. AD is
characterized by the local infiltration of T helper type 2 (Th2) cells. Recent clinical studies have shown important roles of the
Th2 chemokines, CCL22 and CCL17 in the pathogenesis of AD. To investigate whether polymorphisms of the CCL22 gene
affect the susceptibility to AD, we conducted association studies and functional studies of the related variants. We first
resequenced the CCL22 gene and found a total of 39 SNPs. We selected seven tag SNPs in the CCL22 gene, and conducted
association studies using two independent Japanese populations (1
st population, 916 cases and 1,032 controls; 2
nd
population 1,034 cases and 1,004 controls). After the association results were combined by inverse variance method, we
observed a significant association at rs4359426 (meta-analysis, combined P=9.6610
26; OR, 0.74; 95% CI, 0.65–0.85).
Functional analysis revealed that the risk allele of rs4359426 contributed to higher expression levels of CCL22 mRNA. We
further examined the allelic differences in the binding of nuclear proteins by electrophoretic mobility shift assay. The signal
intensity of the DNA-protein complex derived from the G allele of rs223821, which was in absolute LD with rs4359426, was
higher than that from the A allele. Although further functional analyses are needed, it is likely that related variants play a
role in susceptibility to AD in a gain-of-function manner. Our findings provide a new insight into the etiology and
pathogenesis of AD.
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Introduction
Atopic dermatitis (AD) is a pruritic and chronically relapsing
inflammatory skin disease involving disturbed skin barrier
functions, cutaneous inflammatory hypersensitivity and defects in
the antimicrobial immune defense with a strong genetic back-
ground [1]. Predominant infiltration of Th2 cells is a hallmark of
acute atopic AD skin lesions [2]. Most patients with AD have
peripheral blood eosinophilia and increased serum IgE levels,
which are reflected in an increased frequency of peripheral blood
skin-homing Th2 cells producing IL-4, IL-5 and IL-13 [1]. C-C
motif chemokine 22 (CCL22) and CCL17 are high-affinity ligands
for CC-chemokine receptor 4 (CCR4) and induce selective
migration of Th2 cells [3]. CCL22 plays a crucial role in
controlling the trafficking of Th2 cells into sites of allergic
inflammation and is considered to be involved in the pathology of
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7AD [4]. Keratinocytes from patients with AD highly express
thymic stromal lymphopoietin (TSLP), and CCL22 is produced by
TSLP-treated dendritic cells [5]. CCL22 is upregulated in lesional
atopic dermatitis skin compared with healthy skin [6], and
keratinocytes in the epidermal layer of AD skin express CCL17
and CCL22 [7]. Serum levels of CCL22 in AD patients are
significantly higher than those found in normal controls [8], and
the levels correlate positively with disease severity in AD patients
[9]. Strong positive correlations between the levels of CCL17,
CCL22, and total IgE in serum of patients with AD and SCORing
Atopic Dermatitis (SCORAD) have also been reported [10].
Another study reported that overproduction of IgE induced
CCL22 secretion from basophils, which are essential for IgE-
mediated chronic allergic dermatitis [11]. These findings prompt-
Table 1. Frequencies of polymorphisms of the CCL22 gene.
SNP* Location Amino acid MAF{ NCBI{
1 -3075G/A 59-flanking region - 0.125 rs223884
2 -2938G/A 59-flanking region - 0.208 rs223885
3 -2903T/A 59-flanking region - 0.333 rs223886
4 -2668G/T 59-flanking region - 0.458 rs34569362
5 -2550G/C 59-flanking region - 0.458 rs76295899
6 -2511G/T 59-flanking region - 0.458 rs4784799
7 -2191G/C 59-flanking region - 0.042 rs76720124
8 -1795G/A 59-flanking region - 0.458 rs34885482
9 -1775G/T 59-flanking region - 0.083 rs72784894
10 -1618C/T 59-flanking region - 0.458 rs77239447
11 -1515G/T 59-flanking region - 0.333 rs223887
12 -1338A/G 59-flanking region - 0.208 rs182668
13 -961G/A 59-flanking region - 0.208 rs223888
14 -740A/G 59-flanking region - 0.083 rs3760071
15 -488T/C 59-flanking region - 0.333 rs223889 1
16 -215WT/DelG 59-flanking region - 0.333 rs3214179
17 5C/A exon 1 Ala2Asp 0.125 rs4359426 1
18 88C/A intron 1 - 0.458 rs2074543 1
19 493T/C intron 1 - 0.458 rs72784897
20 559G/A intron 1 - 0.333 rs223816
21 902C/T intron 1 - 0.333 rs223817
22 2030G/C intron 2 - 0.208 rs223818 1
23 2134T/C intron 2 - 0.208 rs223819
24 2198T/C intron 2 - 0.208 rs223820
25 2314G/A intron 2 - 0.292 rs598366
26 2936A/G intron 2 - 0.125 rs170359
27 3062A/G intron 2 - 0.458 rs73557194
28 3766T/A intron 2 - 0.042
29 3970G/A intron 2 - 0.125 rs223821
30 4064WT/InsAAAAC intron 2 - 0.125 rs72030112
31 5222T/C 39 UTR - 0.125 rs170360
32 5978WT/DelT 39 UTR - 0.125 rs57450696
33 5979C/G 39 UTR - 0.375 rs57186204
34 6089T/C 39 UTR - 0.125 rs223823
35 6621A/G 39 UTR - 0.458 rs121565 1
36 6910G/A 39 UTR - 0.417 rs658559 1
37 7858C/T 39-flanking region - 0.458 rs3859048 1
38 7883G/A 39-flanking region - 0.458 rs72301
39 8021G/A 39-flanking region - 0.042 rs11865093
*Numbering according to the genomic sequence of CCL22 (AC003665). Position 1 is the A of the initiation codon.
{Minor allele frequencies (MAF) in the screening population (N=12).
{NCBI, number from the dbSNP of NCBI (http://www.ncbi.nlm.nih.gov/SNP/).
1SNPs were genotyped in this study.
doi:10.1371/journal.pone.0026987.t001
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PLoS ONE | www.plosone.org 2 November 2011 | Volume 6 | Issue 11 | e26987Figure 1. Pairwise linkage disequilibrium between 34 SNPs. LD was measured by D9/LOD (upper) and r
2 (lower) estimated using the
Haploview 4.2 program (http://www.broad.mit.edu/mpg/haploview/). Boxed variants were genotyped in this study.
doi:10.1371/journal.pone.0026987.g001
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whether genetic variations of CCL22 contribute to AD suscepti-
bility.
Several association studies using genetic variants of genes CCL17
and CCR4 in the CCR4 pathway have been conducted to discover
geneticcomponents in the pathogenesis of atopicdermatitis [12,13].
A promoter polymorphism of CCL17, -431C.T, increases the
promoter activity and the 431T allele influences higher serum levels
of CCL17 [12], but genetic variants in the CCL17 gene are not
associated with susceptibility to AD. A recent study also reported
that C1014T polymorphism in the CCR4 gene was not associated
with AD [13]. However, those studies were performed with small
sample sizes and without replication studies. Genetic study of the
CCL22 gene has not been conducted.
In this study, we focused on the CCL22 gene, resequenced the
gene regions including all exons and introns, and carried out
linkage disequilibrium mapping. We performed an association
study using two independent populations and functional analyses
of the related variants.
Results
Polymorphisms of the CCL22 gene and LD mapping
We identified a total of 39 polymorphisms (Table 1). We next
performed linkage disequilibrium (LD) mapping and calculated
Table 3. Genotype counts and case-control association test results of seven tag SNPs.
Allele Case Control Frequency of allele 2
db SNP ID 1/2 1/1 1/2 2/2 N 1/1 1/2 2/2 N Case Control P value OR (95%CI)
1st population
rs223889 T/C 321 435 151 907 360 502 161 1023 0.406 0.403 0.82 -
rs4359426 C/A 706 191 12 909 736 269 16 1021 0.118 0.147 0.0072 0.77(0.64–0.93)
rs2074543 G/C 386 404 113 903 447 469 110 1026 0.349 0.336 0.39 -
rs223818 A/G 563 311 39 913 596 369 56 1021 0.213 0.236 0.093 -
rs121565 A/G 294 439 173 906 325 509 195 1029 0.433 0.437 0.82 -
rs658559 G/A 333 434 134 901 374 491 162 1027 0.390 0.397 0.65 -
rs3859048 C/T 399 410 103 912 466 448 108 1022 0.338 0.325 0.40 -
2nd population
rs223889 T/C 369 497 163 1029 364 485 150 999 0.400 0.393 0.65 -
rs4359426 C/A 815 202 12 1029 722 249 22 993 0.110 0.148 0.00037 0.71(0.59–0.86)
rs2074543 G/C 404 484 133 1021 418 459 120 997 0.367 0.351 0.26 -
rs223818 A/G 647 331 42 1020 585 351 57 993 0.203 0.234 0.019 0.84(0.72–0.97)
rs121565 A/G 317 530 179 1026 317 500 180 997 0.433 0.431 0.92 -
rs658559 G/A 389 486 154 1029 363 479 148 990 0.386 0.391 0.71 -
rs3859048 C/T 425 484 117 1026 441 446 113 1000 0.350 0.336 0.35 -
Combined
rs223889 T/C 690 932 314 1936 724 987 311 2022 0.403 0.398 0.63 -
rs4359426 C/A 1521 393 24 1938 1458 518 38 2014 0.114 0.147 0.0000096 0.74(0.65–0.85)
rs2074543 G/C 790 888 246 1924 865 928 230 2023 0.359 0.343 0.16 -
rs223818 A/G 1210 642 81 1933 1181 720 113 2014 0.208 0.235 0.0044 0.86(0.77–0.95)
rs121565 A/G 611 969 352 1932 642 1009 375 2026 0.433 0.434 0.93 -
rs658559 G/A 722 920 288 1930 737 970 310 2017 0.388 0.394 0.56 -
rs3859048 C/T 824 894 220 1938 907 894 221 2022 0.344 0.330 0.21 -
P values of the two populations were calculated by logistic regression analysis under an additive model. The combined P values were calculated using the inverse
variance method. OR, odds ratio; CI, confidence interval; -, not significant.
doi:10.1371/journal.pone.0026987.t003
Table 2. Clinical characteristics of the subjects.
Case Control
1
st population
Source The University of Tokyo
Keio University
Kyushu University
Takao Hospital
Control volunteers
Number of samples 916 1,032
Ethnicity Japanese Japanese
Female 43.6% 33.0%
Age (mean 6 sd) 30.169.5 48.5613.7
2
nd population
Source BioBank Japan University of Tsukuba
Number of samples 1,034 1,004
Ethnicity Japanese Japanese
Female 43.8% 54.4%
Age (mean 6 sd) 30.8612.7 50.069.2
doi:10.1371/journal.pone.0026987.t002
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2 among the 34 polymorphisms
with MAF.10% using the Haploview 4.2 program (Figure 1).
Seven tag SNPs were selected for association studies using tagger
in Haploview 4.2, and these polymorphisms captured 34 of the 34
alleles with a mean r
2 of 0.990 (r
2.0.82). The HapMap JPT
database contains genotype data for six SNPs with MAF.10% in
the region (data not shown). The SNPs examined in this study
covered all six SNPs shown in the HapMap JPT database.
Association of CCL22 SNPs with susceptibility to atopic
dermatitis
We recruited 916 cases and 1,032 control subjects for the 1
st
population and 1,034 cases and 1,004 control subjects for the 2nd
population, respectively (Table 2). We genotyped seven tag SNPs
and all genotype frequencies are shown in Table 3. The rs4359426
(A2D) SNP was associated with AD under an additive genotype
model by logistic regression analysis in the first population
(P=0.0072; OR, 0.77; 95% CI, 0.64–0.93) (Table 3). In a
replication study, rs4359426 was also associated with AD in the
second population (P=0.00037; OR, 0.71; 95% CI, 0.59–0.86)
(Table 3). The direction of association of the SNP was similar in
both of the populations. We combined the results using inverse
variance method, and observed a significant association at
rs4359426 (meta-analysis, P=0.0000096; OR, 0.74; 95% CI,
0.65–0.85) (Table 3). We next performed further mapping analyses
using two genetic variants, rs170360 and rs223823. The two SNPs
were selected from among SNPs that were in strong LD (r
2.0.87)
with rs4359426 (Figure 2). Among the three variants, the strongest
association was observed at rs4359426 (Table 4).
Contribution of 59UTR rs4359426 SNP to mRNA
expression levels of CCL22
Next, using allele-specific transcript quantification (ASTQ), we
evaluated whether the related variants could affect the mRNA
expression level in EBV-transformed lymphoblastoid cells. As
rs4359426 was located at the 16th nucleotide from the 59 end of
the CCL22 gene (NM_002990.3), we were not able to design
primers of the SNP for ASTQ analysis. We therefore designed
PCR primers to encompass a SNP in the 39-UTR of CCL22
(rs170360) that was in strong LD with rs4359426 (Figure 3A). We
isolated total RNA from 24 cell lines that were heterozygous with
rs170360, and genomic DNA was used as a control for equal
biallelic representation. Predicted haplotype frequencies are shown
in Figure 3B. The ratio of PCR products was approximately 1.6
for cDNAs and 1.0 for genomic DNA from 21 subjects who were
heterozygous for rs4359426 (Figure 3C, left panel); however, such
Table 4. Genotype counts and case-control association test results for SNPs rs4359426, rs170360 and rs223823.
Allele Case Control Frequency of allele 2
db SNP ID 1/2 1/1 1/2 2/2 N 1/1 1/2 2/2 N Case Control P value OR (95%CI)
1st population
rs4359426 C/A 706 191 12 909 736 269 16 1021 0.118 0.147 0.0072 0.77(0.64–0.93)
rs170360 T/C 695 199 12 906 734 269 20 1023 0.123 0.151 0.011 0.78(0.65–0.95)
rs223823 T/C 728 170 11 909 765 252 10 1027 0.106 0.132 0.0093 0.77(0.63–0.94)
2nd population
rs4359426 C/A 815 202 12 1029 722 249 22 993 0.110 0.148 0.00037 0.71(0.59–0.86)
rs170360 T/C 792 220 19 1031 728 238 26 992 0.125 0.146 0.055 0.84(0.70–1.00)
rs223823 T/C 823 189 8 1020 780 193 19 992 0.100 0.116 0.11 0.85(0.70–1.04)
Combined
rs4359426 C/A 1521 393 24 1938 1458 518 38 2014 0.118 0.147 0.0000096 0.74(0.65–0.85)
rs170360 T/C 1487 419 31 1937 1462 507 46 2015 0.123 0.151 0.0017 0.81(0.72–0.93)
rs223823 T/C 1551 359 19 1929 1545 445 29 2019 0.106 0.132 0.0030 0.81(0.70–0.93)
P values of the two populations were calculated by logistic regression analysis under an additive model.
The combined P values were calculated using the inverse variance method. OR, odds ratio; CI, confidence interval.
doi:10.1371/journal.pone.0026987.t004
Figure 2. Pairwise linkage disequilibrium (r
2) among eight
SNPs in strong LD with rs4359426 in 94 control subjects. Two
tag SNPs, rs170360 and rs223823, were selected for further association
study. Underlined SNPs were examined.
doi:10.1371/journal.pone.0026987.g002
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homozygous for the C allele at rs4359426 (Figure 3C, right panel).
These results implied an effect of rs4359426 and/or variants in
strong LD with rs4359426 on mRNA expression levels of CCL22.
rs4359426 and rs170360 are in absolute LD in the HapMap
Caucasian populations. We further examined the expression
patterns of rs4359426 and rs170360 using Genevar 3.0.2 dataset,
and confirmed that the expression patterns were similar to our
findings (data not shown).
Transcription factor binding to the rs223821 SNP
As rs4359426 was in absolute LD with rs170359, rs223821 and
rs72030112 (n=94) (Figure 2), we further examined the allelic
differences of these three SNPs in the binding of nuclear proteins
by electrophoretic mobility shift assay (EMSA). We could not find
any specific binding of nuclear factor(s) to oligonucleotides
containing rs170359 and rs72030112. However, we observed that
the signal intensity of the DNA-protein complex derived from the
G allele of rs223821 was higher than that from the A allele in the
presence of THP-1 nuclear extract stimulated with LPS (1 mg/ml)
(Figure 4). We confirmed that the complex was diminished by an
excess amount of a non-labeled allele-specific competitor probe
(Figure 4). This result suggested that an unidentified nuclear
factor(s) interacted with the genomic region at intron 2 of CCL22
and the SNP might have an allele-specific effect on expression
through varying affinity for a transcription factor.
Discussion
CCL22 plays an important role in the recruitment of Th2 cells
into the inflammatory lesions of Th2-related diseases such as AD
[14]. A recent study reported upregulation of CCL17, CCL18 and
CCL22 expression in patients with AD, and suggested that the
disease-specific chemokines might recruit specific memory T-cell
subsets into the skin [15]. The plasma levels of CCL22 are
Figure 3. Allelic imbalance of gene expression of CCL22 in EBV-transformed cells with heterozygous genotypes. (A) Genomic
structures, locations and LD of the two SNPs. (B) Haplotypes for the two SNPs in the 1
st population. (C) The allelic ratio of PCR products from
individuals. Heterozygous (left) and homozygous (right) at rs4359426. *Two-tailed P=0.0000006 by the Mann-Whitney U test.
doi:10.1371/journal.pone.0026987.g003
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correlate with disease severity [7,10]. We identified and replicated
the rs4359426 (A2D) variant of CCL22, which was significantly
associated with AD. rs4359426 is a non-synonymous SNP and
causes an amino acid substitution in the signal peptide-encoding
region. We examined the influence of the amino acid substitution
on the structure using SIFT (Sorting Intolerant From Tolerant)
software, and the substitution at position 2 from Ala to Asp was
predicted to be tolerated. In addition, no possible impacts of the
amino acid substitution on the structure and function of CCL22
were predicted by PolyPhen-2 (polymorphism phenotyping v2).
Functional analyses of the related variants of CCL22 polymor-
phisms showed that the susceptible allele of rs4359426 might be
involved in higher mRNA expression in ASTQ analysis. We
confirmed that the expression patterns from Genevar 3.0.2 dataset
were similar to our findings. We also demonstrated that the
genomic fragment including the risk allele of rs223821 had much
higher binding affinity to the nuclear factor(s). Although it is
unclear whether higher mRNA expression is influenced by altering
expression enhancer activity or mRNA stability, polymorphisms in
the CCL22 gene appear to be a genetic component of the
pathologic mechanisms leading to atopic dermatitis, putatively via
increased CCL22 mRNA expression.
Genetic studies reveal underlying cellular pathways, and in
some cases, point to new therapeutic approaches. A recent study
using a humanized model of asthma showed a critical role for DC-
derived CCL17 and CCL22 in attracting Th2 cells and inducing
airway inflammation [16]. In the study, administration of a
CCR4-blocking antibody abolished airway eosinophilia, goblet cell
hyperplasia, IgE synthesis and bronchial hyperreactivity [16]. IL-
13 is an important mediator of Th2 immune responses, and there
many IL-13-positive cells in AD skin lesions [17]. A recent study
has shown that IL-13 induces a significant increase in the
expression of CCL22 in human keratinocytes, and blocking of
CCL22 in IL-13-stimulated cells results in 70–90% inhibition in
migration of CD4+CCR4+ T cells [18]. These findings suggest
that targeting the CCL22/CCR4 pathway might be therapeuti-
cally efficacious as a new treatment for atopic dermatitis.
The involvement of CCL22 has been reported in several
immune-mediated diseases. A recent study has shown by
immunohistochemistry that CCL22 is not expressed in normal
skin and is markedly expressed in the lesions of atopic dermatitis,
allergic contact dermatitis, and psoriasis vulgaris [19]. Another
report has shown that CCL22 is present within the synovial
membrane in rheumatoid arthritis and osteoarthritis patients and
in high amounts in the synovial fluid of patients with rheumatoid
arthritis and psoriatic arthritis [20]. To examine whether the
functional SNPs found in this study are associated with those
diseases will be needed for understanding of the interconnectivity
of the molecular mechanisms underlying distinct diseases.
In summary, we found a significant association between
susceptibility to AD and polymorphisms affecting CCL22 expres-
sion in Japanese populations. Our findings strongly support the
important role of CCL22 in AD. Although the effect of the non-
synonymous SNP on protein function remains unclear, it is likely
that related variants play a role in susceptibility to AD in a gain-of-
function manner. Further functional analyses and replication
studies in other populations are needed; however, our findings
provide insights into the pathophysiology of AD.
Materials and Methods
Subjects
A total of 1,950 case subjects with AD were recruited from
several hospitals as described [21]. Case subjects in a second
population were obtained from the BioBank Japan [22]. All case
subjects were diagnosed according to the criteria of Hanifin and
Rajka [23]. A total of 1,032 control volunteers in the first set who
had no history of AD were recruited by detailed physicians’
interviews. For the second set, a total of 1,004 controls who had
never been diagnosed with AD were recruited during their annual
health checkup in the University of Tsukuba (Table 2). All
individuals were Japanese and gave written informed consent to
participate in the study. This research project was approved by the
ethics committees at the Institute of Medical Science, the
University of Tokyo and the RIKEN Yokohama Institute.
Resequencing of the CCL22 gene and genotyping
We first resequenced the CCL22 region to identify genetic
variations using DNA from 12 subjects with AD. We surveyed the
gene from 3 kb of the 59 flanking region to a 1 kb continuous 39
flanking region of the last exon on the basis of genomic sequences
from the NCBI database (NC_000016.9). The PCR product was
reacted with BigDye Terminator v3.1 (Applied Biosystems), and
sequences were assembled and polymorphisms identified using the
SEQUENCHER program (Gene Codes Corporation, Ann Arbor,
MI).
Genotyping of the seven SNPs in CCL22 was performed by the
TaqMan
TM allele-specific amplification (TaqMan-ASA) method
(Applied Biosystems) and multiplex-PCR based Invader assay
(Third Wave Technologies).
Allele-specific transcript quantification (ASTQ)
We conducted allelic expression analyses by TaqMan assay
using SNP genotyping probes as described [24]. EBV-transformed
lymphoblastoid cells were obtained from the Health Science
Research Resources Bank of Japan. Genomic DNA was used as a
Figure 4. Electrophoretic mobility shift assays of rs223821.
EMSA was performed using nuclear extracts from THP-1 cells stimulated
with LPS (1.0 mg/ml) for 1 hour. DIG-labeled oligonucleotides corre-
sponding to the G allele (lanes 1–5) and A allele (lanes 6–10) were used
as probes. Three independent experiments were performed with similar
results.
doi:10.1371/journal.pone.0026987.g004
Association between CCL22 and Atopic Dermatitis
PLoS ONE | www.plosone.org 7 November 2011 | Volume 6 | Issue 11 | e26987control for equal biallelic representation. The allelic ratio for each
cDNA and genomic DNA was measured.
Electrophoresis Mobility Shift Assay
EMSA was performed using nuclear extracts from THP-1 cells
stimulated with LPS (1.0 mg/ml) for 1 hour. DIG-labeled
oligonucleotides corresponding to the G allele (lanes 1–5) and A
allele (lanes 6–10) were used as probes. The oligonucleotide
sequences were 59-ATCGCCTGAACCCGGGAGTTGGAG-
GTT for the G allele and 59-ATCGCCTGAACCCAG-
GAGTTGGAGGTT for the A allele. For competition, a 100-
fold excess of unlabeled G or A allele oligonucleotides or unrelated
oligonucleotides (Un) (TFIID) was used.
Statistical analysis
We calculated allele frequencies and tested agreement with
Hardy-Weinbergequilibrium usinga chi-square goodness-of-fittest.
Wethencompareddifferencesintheallelefrequenciesbetween case
and control subjects by logistic regression analysis under an additive
model and calculated odds ratios (ORs) with 95% confidence
intervals (CIs). Results for the 1st and 2nd populations were
combined by fixed effect inverse-variance method using Genome-
Wide Association Meta Analysis (GWAMA, http://www.well.ox.
ac.uk/gwama/tutorial.shtml) [25]. We applied Bonferroni correc-
tions, the multiplication of P values by the number of variants
investigated. Corrected P values of less than 0.05 were judged to be
significant. The expression patterns of SNPs were obtained from
Genevar (GENe Expression VARiation) 3.0.2 (Wellcome Trust
Sanger Institute). We examined the influence of amino acid
substitution on the structure using SIFT software (http://sift.jcvi.
org/) and PolyPhen-2 (polymorphism phenotyping v2) (http://
genetics.bwh.harvard.edu/pph2/).
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